FDA Grants Orphan Drug Designation to Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
- Details
- Category: Bayer
Bayer HealthCare announced that its investigational anti-cancer compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA).
Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
GSK revises US Avandia label to include new restrictions on use
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines (Avandia®, Avandamet® and Avandaryl®) to include additional safety information and restrictions on the use of these medicines.
Pfizer To Acquire Ferrosan's Consumer Healthcare Business
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has entered into a definitive agreement to purchase Ferrosan's consumer healthcare business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited.
Nycomed to acquire Colombian company Farmacol
- Details
- Category: Nycomed
Nycomed is expanding its presence in Latin America through the acquisition of Laboratorios Farmacol S.A., a Colombia based pharmaceutical company, which has a strong presence in the areas of gastroenterology, respiratory and gynaecology.
New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan
- Details
- Category: Pfizer
Pfizer Japan Inc. ("Pfizer", headquarters: Shibuya-ku, Tokyo) and Takeda Pharmaceutical Company Limited ("Takeda", headquarters: Chuo-ku, Tokyo) announced an agreement to extend the period for co-promotion in Japan for the rheumatoid arthritis (RA) drug Enbrel® (generic name: etanercept).
GSK's full year trading update
- Details
- Category: GlaxoSmithKline
Total Group turnover for the year declined 1% to £28.4 billion, with pharmaceutical turnover down 2% to £23.4 billion and Consumer Healthcare sales up 5% to £5.0 billion. Excluding pandemic products, Valtrex and Avandia, Group sales were up 4.5% for the year.
More Pharma News ...
- The Roche Group posted solid overall results in 2010
- Novo Nordisk increased operating profit by 27% in 2010
- Pfizer Reports Fourth-Quarter and Full-Year 2010 Results
- Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc.
- Genzyme Will Allow sanofi-aventis to Conduct Due Diligence
- Innovation drives Novartis to double-digit growth for 2010
- Bayer and Zydus Cadila sign Joint Venture Agreement